Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants-Reference-Cited by-同舟云学术

Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants

Published:2011-04 Issue:4 Volume:15 Page:e249-e256
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Kosalaraksa Pope,Thisyakorn Usa,Benjaponpitak Suwat,Chokephaibulkit Kulkanya,Santos-Lima Eduardo

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference32 articles.

1. United Nations pre-qualified vaccines: WHO list of vaccines for purchase by UN agencies. Available at: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html (accessed July 20, 2010).

2. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations;Vidor;Hum Vaccin,2008

3. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity;Diminsky;Vaccine,1997

4. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years;Tregnaghi;Vaccine,2010

5. Maçias M, Lanata C, Zambrano B, Santos-Lima E. Safety and immunogenicity of an investigational hexavalent DTaP–IPV–Hep B–PRP-T vaccine at 2, 4, 6 months compared to licensed vaccines in Latin America. Abstract 014. Presented at the 6th Congress of the World Society for Pediatric Infectious Diseases, Buenos Aires, Argentina, November 19–22, 2009.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A worldwide overview for hexavalent vaccines and a glimpse into Turkiye’s perspective;Human Vaccines & Immunotherapeutics;2024-05-23

2. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016);Human Vaccines & Immunotherapeutics;2024-02-08

3. DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure;Expert Review of Vaccines;2023-12-06

4. Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand;Pediatric Infectious Disease Journal;2023-04-27

5. Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries;Human Vaccines & Immunotherapeutics;2023-01-02